Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
According to a new study, genetic testing is more likely to turn up false positives for black people than white people when looking for mutations related to hypertrophic cardiomyopathy.
We live in an age where young skin is revered, tan is in and sun safe behavior is at an all-time low. Researchers from the University of Surrey have conducted a study on which method promotes young women to protect their skin from the sun and ultimately, skin cancer.
AT&T may already be providing your cellphone service, but now it’s delivering connectivity for wearable medical devices as well. A new partnership between Biotricity, a medical diagnostic and consumer healthcare tech company, and AT&T means that the service provider is now responsible for granting “near real-time connectivity for [Biotricity devices’] data transmission.”
In a Health Affairs blog post, Association of Academic Health Centers (AAHC) President Steven Wartman, MD, PhD, wrote about ways he believes graduate medical education (GME) and residency can be improved.
A medical study might be envisioned, executed and published during one PhD candidate’s advanced degree study course. But that’s not the best way to actually learn new things related to science and medicine, according to The Atlantic.
Kentucky has filed a lawsuit against Johnson & Johnson’s medical device unit, Ethicon, alleging it concealed and purposely misrepresented the risks involved in its surgical transvaginal mesh products to physicians and patients.
The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.
